Elevance Health (A58) Stock Forecast & Price Target

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

A58 Analyst Ratings

Moderate Buy

13 Buy

6 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Elevance

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

A58 Stock 12 Month Forecast

Average Price Target

€390.35

▲(17.86% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is €390.35 with a high forecast of €432.63 and a low forecast of €341.41. The average price target represents a 17.86% change from the last price of €331.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"240":"€240","433":"€433","288.25":"€288.3","336.5":"€336.5","384.75":"€384.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":432.63266442,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€432.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":390.35397030666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€390.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":341.41493397,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€341.41</span>\n  </div></div>","useHTML":true}}],"tickPositions":[240,288.25,336.5,384.75,433],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,329.2,337.15635880153843,345.11271760307693,353.0690764046154,361.0254352061539,368.9817940076923,376.93815280923076,384.89451161076926,392.8508704123077,400.8072292138462,408.76358801538464,416.7199468169231,424.6763056184616,{"y":432.63266442,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,329.2,333.90415156205125,338.6083031241026,343.31245468615384,348.0166062482051,352.72075781025643,357.4249093723077,362.12906093435896,366.8332124964103,371.53736405846155,376.2415156205128,380.9456671825641,385.6498187446154,{"y":390.35397030666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,329.2,330.1396103053846,331.0792206107692,332.01883091615383,332.95844122153846,333.89805152692304,334.8376618323077,335.7772721376923,336.71688244307694,337.6564927484615,338.59610305384615,339.5357133592308,340.47532366461536,{"y":341.41493397,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":241.484,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":265.476,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":277.012,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":270.119,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":284.397,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":291.402,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":285.661,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":259.035,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":251.665,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":319.188,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":342.193,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":337.8,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":329.2,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€432.63

Average Price Target€390.35

Lowest Price Target€341.41

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Lance Wilkes

Bernstein

€423.95

Buy

28.00%

Upside

Reiterated

07/21/26

Elevance Health (ELV) Gets a Buy from Bernstein

Andrew Mok CFA

Barclays

€397.01

Buy

19.87%

Upside

Assigned

07/20/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (NASDAQ: IOVA), Elevance Health (NYSE: ELV) and InnovAge Holding (NASDAQ: INNV)

Erin Wright

Morgan Stanley

€350.97

Hold

5.97%

Upside

Assigned

07/17/26

Erin Wright Maintains Hold Rating on Elevance with Unchanged $404 Price Target Amid Mixed Results and Cautious Outlook

Whit Mayo

Leerink Partners

€316.22→€343.15

Hold

3.61%

Upside

Reiterated

07/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (NASDAQ: TXG), Elevance Health (NYSE: ELV) and Johnson & Johnson (NYSE: JNJ)

Ryan Langston

TD Cowen

€403.96

Buy

21.97%

Upside

Reiterated

07/17/26

TD Cowen Keeps Their Buy Rating on Elevance Health (ELV)

David S Macdonald

Truist Financial

€412.65

Buy

24.59%

Upside

Reiterated

07/16/26

Elevance Health price target raised to $475 from $450 at TruistElevance Health price target raised to $475 from $450 at Truist

David Windley

Jefferies

€339.68→€390.93

Buy

18.04%

Upside

Reiterated

07/16/26

Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL), Tenaya Therapeutics (NASDAQ: TNYA) and Elevance Health (NYSE: ELV)

Stephen Baxter

Wells Fargo

€427.42→€410.91

Buy

24.07%

Upside

Assigned

07/16/26

Elevance Health price target raised to $492 from $391 at Wells FargoElevance Health price target raised to $492 from $391 at Wells Fargo

Kevin Fischbeck

Bank of America Securities

€399.62

Buy

20.66%

Upside

Reiterated

07/16/26

Fischbeck Reiterates Buy on Elevance Health, Keeps $460 Price Target Unchanged Amid Cautious Guidance and Improving Fundamentals

Michael Ha

Robert W. Baird

€287.55→€341.41

Hold

3.08%

Upside

Reiterated

07/16/26

Elevance Health price target raised to $393 from $331 at BairdElevance Health price target raised to $393 from $331 at Baird

Amit Daryanani

Evercore ISI

―

Hold

―

Reiterated

07/15/26

Regulatory and Cost Pressures Balance Solid Fundamentals: Amit Daryanani Maintains Hold on Elevance Health

Ben Hendrix

RBC Capital

€381.38→€368.35

Hold

11.22%

Upside

Reiterated

07/15/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (NASDAQ: ATAI), Alnylam Pharma (NASDAQ: ALNY) and Elevance Health (NYSE: ELV)

Scott Fidel

Goldman Sachs

€321.43→€343.15

Hold

3.61%

Upside

Reiterated

07/15/26

Elevance Health price target raised to $395 from $370 at Goldman SachsElevance Health price target raised to $395 from $370 at Goldman Sachs

Jason Cassorla

Guggenheim

€346.63→€395.28

Buy

19.35%

Upside

Reiterated

07/15/26

Guggenheim Sticks to Their Buy Rating for Elevance Health (ELV)

Ann Hynes

Mizuho Securities

€403.96→€408.31

Buy

23.28%

Upside

Reiterated

07/13/26

Mizuho Securities Keeps Their Buy Rating on Elevance Health (ELV)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Lance Wilkes

Bernstein

€423.95

Buy

28.00%

Upside

Reiterated

07/21/26

Elevance Health (ELV) Gets a Buy from Bernstein

Andrew Mok CFA

Barclays

€397.01

Buy

19.87%

Upside

Assigned

07/20/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (NASDAQ: IOVA), Elevance Health (NYSE: ELV) and InnovAge Holding (NASDAQ: INNV)

Erin Wright

Morgan Stanley

€350.97

Hold

5.97%

Upside

Assigned

07/17/26

Erin Wright Maintains Hold Rating on Elevance with Unchanged $404 Price Target Amid Mixed Results and Cautious Outlook

Whit Mayo

Leerink Partners

€316.22→€343.15

Hold

3.61%

Upside

Reiterated

07/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (NASDAQ: TXG), Elevance Health (NYSE: ELV) and Johnson & Johnson (NYSE: JNJ)

Ryan Langston

TD Cowen

€403.96

Buy

21.97%

Upside

Reiterated

07/17/26

TD Cowen Keeps Their Buy Rating on Elevance Health (ELV)

David S Macdonald

Truist Financial

€412.65

Buy

24.59%

Upside

Reiterated

07/16/26

Elevance Health price target raised to $475 from $450 at TruistElevance Health price target raised to $475 from $450 at Truist

David Windley

Jefferies

€339.68→€390.93

Buy

18.04%

Upside

Reiterated

07/16/26

Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL), Tenaya Therapeutics (NASDAQ: TNYA) and Elevance Health (NYSE: ELV)

Stephen Baxter

Wells Fargo

€427.42→€410.91

Buy

24.07%

Upside

Assigned

07/16/26

Elevance Health price target raised to $492 from $391 at Wells FargoElevance Health price target raised to $492 from $391 at Wells Fargo

Kevin Fischbeck

Bank of America Securities

€399.62

Buy

20.66%

Upside

Reiterated

07/16/26

Fischbeck Reiterates Buy on Elevance Health, Keeps $460 Price Target Unchanged Amid Cautious Guidance and Improving Fundamentals

Michael Ha

Robert W. Baird

€287.55→€341.41

Hold

3.08%

Upside

Reiterated

07/16/26

Elevance Health price target raised to $393 from $331 at BairdElevance Health price target raised to $393 from $331 at Baird

Amit Daryanani

Evercore ISI

―

Hold

―

Reiterated

07/15/26

Regulatory and Cost Pressures Balance Solid Fundamentals: Amit Daryanani Maintains Hold on Elevance Health

Ben Hendrix

RBC Capital

€381.38→€368.35

Hold

11.22%

Upside

Reiterated

07/15/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (NASDAQ: ATAI), Alnylam Pharma (NASDAQ: ALNY) and Elevance Health (NYSE: ELV)

Scott Fidel

Goldman Sachs

€321.43→€343.15

Hold

3.61%

Upside

Reiterated

07/15/26

Elevance Health price target raised to $395 from $370 at Goldman SachsElevance Health price target raised to $395 from $370 at Goldman Sachs

Jason Cassorla

Guggenheim

€346.63→€395.28

Buy

19.35%

Upside

Reiterated

07/15/26

Guggenheim Sticks to Their Buy Rating for Elevance Health (ELV)

Ann Hynes

Mizuho Securities

€403.96→€408.31

Buy

23.28%

Upside

Reiterated

07/13/26

Mizuho Securities Keeps Their Buy Rating on Elevance Health (ELV)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elevance Health

3 Months

Kevin FischbeckBank of America Securities

Success Rate

12/19 ratings generated profit

Average Return

+0.84%

Copying Kevin Fischbeck's trades and holding each position for 3 Months would result in 63.16% of your transactions generating a profit, with an average return of +0.84% per trade.

1 Year

A.J. RiceUBS

Success Rate

23/30 ratings generated profit

Average Return

+19.04%

Copying A.J. Rice's trades and holding each position for 1 Year would result in 76.67% of your transactions generating a profit, with an average return of +19.04% per trade.

2 Years

A.J. RiceUBS

Success Rate

26/30 ratings generated profit

Average Return

+37.79%

Copying A.J. Rice's trades and holding each position for 2 Years would result in 86.67% of your transactions generating a profit, with an average return of +37.79% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

A58 Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, A58 has received 19 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. A58 average Analyst price target in the past 3 months is 390.35.

Each month's total comprises the sum of three months' worth of ratings.

A58 Financial Forecast

A58 Earnings Forecast

Next quarter’s earnings estimate for A58 is €4.08 with a range of €3.95 to €4.73. The previous quarter’s EPS was €6.46. A58 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year A58 has Performed in-line its overall industry.

A58 Sales Forecast

Next quarter’s sales forecast for A58 is €42.72B with a range of €41.44B to €44.22B. The previous quarter’s sales results were €43.77B. A58 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year A58 has Performed in-line its overall industry.

A58 Stock Forecast FAQ

What is DE:A58’s average 12-month price target, according to analysts?

Based on analyst ratings, Elevance Health’s 12-month average price target is 390.35.

What is DE:A58’s upside potential, based on the analysts’ average price target?

Elevance Health has 17.86% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Elevance Health a Buy, Sell or Hold?

Elevance Health has a consensus rating of Moderate Buy, which is based on 13 buy ratings, 6 hold ratings and 0 sell ratings.

What is Elevance Health’s share price target?

The average share price target for Elevance Health is 390.35. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €432.63 ,and the lowest forecast is €341.41. The average share price target represents 17.86% Increase from the current price of €331.2.

What do analysts say about Elevance Health?

Elevance Health’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of Elevance Health?

To buy shares of DE:A58, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Elevance Health (A58) Stock Forecast & Price Target

A58 Analyst Ratings

A58 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Elevance Health

A58 Analyst Recommendation Trends

A58 Financial Forecast

A58 Earnings Forecast

A58 Sales Forecast

A58 Stock Forecast FAQ

Detailed List of Analyst Forecasts